WO2009033078A3 - Compositions et procédés pour maîtriser les taux de cholestérol - Google Patents
Compositions et procédés pour maîtriser les taux de cholestérol Download PDFInfo
- Publication number
- WO2009033078A3 WO2009033078A3 PCT/US2008/075471 US2008075471W WO2009033078A3 WO 2009033078 A3 WO2009033078 A3 WO 2009033078A3 US 2008075471 W US2008075471 W US 2008075471W WO 2009033078 A3 WO2009033078 A3 WO 2009033078A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- hdl
- methods
- patient
- cholesterol levels
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 230000001965 increasing effect Effects 0.000 abstract 3
- 230000002195 synergetic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- WSYRBHQWMXTCHQ-SFIKJRKMSA-N (2s)-n-[(2r)-1-[[(2s)-1-[[(2r)-1-[[(2r)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-[[( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 WSYRBHQWMXTCHQ-SFIKJRKMSA-N 0.000 abstract 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000011010 flushing procedure Methods 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un procédé pour réduire les bouffées congestives chez un patient et pour augmenter les taux de HDL et/ou HDL-2b chez un patient, par administration de compositions au patient uniquement deux fois par jour, de 30 à 60 minutes après le déjeuner et de 30 à 60 minutes après le dîner. Dans certains modes de réalisation, les compositions comprennent un antagoniste de protéine G d'adipocyte, un agoniste de PPAR-α et un agoniste de PPAR-γ avec des quantités efficaces pour conférer un effet thérapeutique synergique augmentant le HDL et/ou un effet thérapeutique synergique augmentant le HDL-2b.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/899,284 US20080058292A1 (en) | 2003-10-29 | 2007-09-05 | Method for increasing HDL and HDL-2b levels |
| US11/899,284 | 2007-09-05 | ||
| US96779707P | 2007-09-07 | 2007-09-07 | |
| US60/967,797 | 2007-09-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009033078A2 WO2009033078A2 (fr) | 2009-03-12 |
| WO2009033078A3 true WO2009033078A3 (fr) | 2009-08-20 |
Family
ID=40429379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/075465 WO2009033072A1 (fr) | 2007-09-05 | 2008-09-05 | Compositions et procédés pour maîtriser les taux de cholestérol |
| PCT/US2008/075471 WO2009033078A2 (fr) | 2007-09-05 | 2008-09-05 | Compositions et procédés pour maîtriser les taux de cholestérol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2008/075465 WO2009033072A1 (fr) | 2007-09-05 | 2008-09-05 | Compositions et procédés pour maîtriser les taux de cholestérol |
Country Status (1)
| Country | Link |
|---|---|
| WO (2) | WO2009033072A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872127A1 (fr) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
| EP3622948A1 (fr) | 2018-09-11 | 2020-03-18 | I.P.S. International Products & Services S.r.l. | Formulations multicouches à double débit de libération d'un ou plusieurs principes actifs |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US20040097593A1 (en) * | 1999-11-08 | 2004-05-20 | Partha Neogi | Compounds for treatment of inflammation, diabetes and related disorders |
| US20050148556A1 (en) * | 2003-10-29 | 2005-07-07 | Raif Tawakol | Compositions and methods for increasing HDL and HDL-2b levels |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070087048A1 (en) * | 2001-05-31 | 2007-04-19 | Abrams Andrew L | Oral dosage combination pharmaceutical packaging |
| ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
| US20050267091A1 (en) * | 2004-05-25 | 2005-12-01 | Roger Berlin | Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses |
-
2008
- 2008-09-05 WO PCT/US2008/075465 patent/WO2009033072A1/fr active Application Filing
- 2008-09-05 WO PCT/US2008/075471 patent/WO2009033078A2/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US20040097593A1 (en) * | 1999-11-08 | 2004-05-20 | Partha Neogi | Compounds for treatment of inflammation, diabetes and related disorders |
| US20050148556A1 (en) * | 2003-10-29 | 2005-07-07 | Raif Tawakol | Compositions and methods for increasing HDL and HDL-2b levels |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009033072A1 (fr) | 2009-03-12 |
| WO2009033078A2 (fr) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004075832A3 (fr) | Methodes et compositions de traitement de douleurs chroniques au moyen de la dhea et de derives de celle-ci | |
| IL177717A0 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
| WO2008003007A3 (fr) | Compositions et procédés destinés au traitement d'infections parasitaires | |
| TW200731968A (en) | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | |
| EP1977746B8 (fr) | Procédés et compositions pour la réduction des effets indésirables de traitements thérapeutiques | |
| WO2007087068A3 (fr) | Inhibiteurs de tyrosine kinase et leurs utilisations | |
| GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
| WO2006130522A3 (fr) | Methodes et compositions pour traiter des troubles psychotiques | |
| HK1186127A1 (zh) | 通過給予神經生長因子拮抗劑及其組合物來治療骨關節炎疼痛的方法 | |
| WO2010132882A3 (fr) | Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation | |
| WO2007081710A3 (fr) | Modalités de traitement pour maladies autoimmunes | |
| WO2007058990A3 (fr) | Therapie a base d’inhibiteurs de cytokine | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| HK1121936A1 (en) | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels | |
| WO2009050136A3 (fr) | Procédé de traitement du syndrome de cushing | |
| IL198460A (en) | Use of 3 alpha-androstandiol and a1ht-5 agonist for the preparation of on-demand sexual dysfunction medications | |
| IL198723A0 (en) | Methods and compositions for therapeutic treatment | |
| ZA200807802B (en) | Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis | |
| WO2010014595A3 (fr) | Méthodes et compositions d'administration d'agents thérapeutiques dans le traitement de troubles associés aux lymphocytes b | |
| WO2009035634A3 (fr) | Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3 | |
| WO2005041878A3 (fr) | Compositions et procedes pour augmenter les niveaux de hdl et hdl-2b | |
| WO2008057196A3 (fr) | Procédés et compositions utilisant des composés immunomodulateurs pour le traitement et la gestion de la spirochète et autres maladies à bactéries intracelulaires obligées | |
| WO2010030976A3 (fr) | Procédés et compositions destinés à inhiber l'athérosclérose et une inflammation vasculaire | |
| WO2007133796A3 (fr) | Procédés et compositions de traitement de l'apnée du sommeil | |
| WO2011011706A3 (fr) | Méthodes et compositions pour le traitement ou la prévention de maladies auto-immunes utilisant des agents immunomodulateurs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08829108 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24.06.2010) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08829108 Country of ref document: EP Kind code of ref document: A2 |